MDMA a Potential Treatment for Autism, Says MindMed
Mind Medicine (MindMed) Inc (Nasdaq: MNMD) will present preclinical data of MM-402, the Company’s proprietary form of the R-enantiomer of 3,4-Methylenedioxymethamphetamine (MDMA), in a model for autism spectrum disorder (ASD) at the 36th Annual ECNP Congress that is being held in Barcelona, Spain from October 7-10, 2023.
MindMed expects to initiate a Phase 1 clinical trial of MM-402 later this year.
Robert Barrow, Chief Executive Officer and Director of MindMed, said, “We continue to demonstrate in preclinical models the potential of our MM-402 product candidate to improve pro-social effects while reducing the stimulant activity and other unwanted effects.”
Highlights
The late-breaking poster entitled “MM-402 demonstrates better efficacy than S(+)-3,4-MDMA or (±)-3,4-MDMA in Fmr1 knockout mice, an animal model of autism spectrum disorder” will be presented on Sunday, October 8, 2023 at 12:35 pm CET.
This study demonstrated that administration of MM-402 increased social interaction in a characterized preclinical model of ASD.
MM-402 exhibited a robust effect on social interaction and was more potent than both S-MDMA and racemic MDMA with reduced hyperactivity effects.
About Mind Medicine
MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders.
MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
